检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:周进明[1] 彭秋平[2] 周琪[2] 钟大平[2] 黄树涛[2] 施绍用[2] 梁后杰[2]
机构地区:[1]解放军第521医院,137001 [2]第三军医大学西南医院肿瘤科,重庆400038
出 处:《临床肿瘤学杂志》2009年第11期969-973,共5页Chinese Clinical Oncology
基 金:国家自然科学基金资助项目(30171067)
摘 要:目的:探讨地塞米松(Dex)体外抑制结肠癌细胞株的增殖并诱导其凋亡的作用机制。方法:采用MTT及流式细胞仪检测细胞增殖抑制及凋亡,RT-PCR检测GR、IκB及Bcl-2的表达改变,凝胶迁移或电泳迁移率实验(EMSA)检测Dex作用过程中的NF-κB活性改变。结果:Dex体外作用后,对4种结肠癌细胞株LoVo、HCT-116、HT-29及SW-480均有抑制作用,LoVo和HCT-116细胞作用最显著。流式细胞仪检测显示,Dex(1×10-4mol/L)诱导72 h后,在LoVo和HCT-116细胞检测到细胞凋亡和坏死峰,明显高于未加Dex的对照组,具有显著性差异。RT-PCR检测显示Dex作用后GRα、IκB表达升高,Bcl-2无明显改变,EMSA结果也显示NF-κB活性明显降低。结论:地塞米松可能通过上调GRα、IκB表达,抑制NF-κB活性来抑制LoVo细胞的增殖,并诱导其凋亡。Objective:To explore the mechanism of apoptosis induced by dexamethasone in human colon carcinoma cell lines in vitro.Methods:GR protein was determined by immunohistochemistry.Proliferation and apoptosis was detected by MTT and flow cytometer.The mRNA expression of GRα,IκB and Bcl-2 was examined by semi-quantitative RT-PCR.The activity of NF-κB was measured by EMSA.Results:The glucocorticoid receptor was determined in LoVo and HCT-116,not in HT-29 and SW-480.Dexamethasone had an inhibitory effect on four kinds of human colon cancer cell lines,respectively.LoVo and HCT-116 cells were more sensitive.Apoptosis and necrosis cusps were investigated by flow cytometer in LoVo and HCT-116,the rates of apoptosis and necrosis were higher than those in the control groups without dexamethasone.The supression of NF-κB activity,up-regulation of the mRNA expression of GRα and IκB occurred in LoVo cells 6,12 and 24 hours after dexamethasone treatment.The expression of Bcl-2 was not changed in LoVo cell.Conclusion:The mechanism of apoptosis and inhibition of proliferation induced by dexamethasone in human colon carcinoma cell may involve up-regulation of GRα and IκB and supression of NF-κB activity.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145